X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Altuvoct (efanesoctocog alfa) is a once-weekly and high-sustained factor VIII replacement therapy, approved for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A.
Lead Product(s): Efanesoctocog Alfa
Therapeutic Area: Genetic Disease Product Name: Altuvoct
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2024
Details:
Gamifant (emapalumab) is an anti-IFNγ monoclonal antibody that binds free and receptor-bound IFNγ, neutralizing its biological activity. Emapalumab is currently in Phase lll development for MAS.
Lead Product(s): Emapalumab
Therapeutic Area: Immunology Product Name: Gamifant
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2024
Details:
Aspaveli (pegcetacoplan) got approved an indication extension for treatment of PNH. It binds to the complement protein C3, which is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria who have haemolytic anaemia.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Rare Diseases and Disorders Product Name: Aspaveli
Highest Development Status: Phase IVProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Details:
BIVV001 (efanesoctocog alfa) is a once-weekly and high-sustained factor VIII replacement therapy, which is currently being evaluated for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A.
Lead Product(s): Efanesoctocog Alfa
Therapeutic Area: Genetic Disease Product Name: BIVV001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2024
Details:
DOPTELET® (avatrombopag maleate), an oral thrombopoietin receptor agonist, which is indicated for the of thrombocytopenia and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
Lead Product(s): Avatrombopag Maleate
Therapeutic Area: Immunology Product Name: Doptelet
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory gout.
Lead Product(s): Pegadricase,ImmTOR
Therapeutic Area: Rheumatology Product Name: SEL-212
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Selecta Biosciences
Deal Size: $705.0 million Upfront Cash: $75.0 million
Deal Type: Licensing Agreement October 31, 2023
Details:
The acquisition strengthens Sobi’s leading haematology franchise by adding Vonjo (pacritinib), a novel oral kinase inhibitor that inhibits JAK2, IRAK1 and ACRV1, while sparing JAK1, for the treatment of adults with myelofibrosis. Vonjo obtained accelerated approval by the FDA.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: Phase IVProduct Type: Small molecule
Recipient: CTI BioPharma Corp
Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million
Deal Type: Acquisition June 26, 2023
Details:
Syfovre™ (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). It targets C3 to provide comprehensive control of the complement cascade, part of the body’s immune system.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Neurology Product Name: Syfovre
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Recipient: Apellis Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Altuviiio (efanesoctocog alfa) is a novel and investigational recombinant factor VIII therapy with the potential to deliver near-normal factor activity levels, extending bleed protection in a once-weekly dose for people with haemophilia A.
Lead Product(s): Efanesoctocog Alfa
Therapeutic Area: Genetic Disease Product Name: Altuviiio
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2023
Details:
The acquisition will diversify Sobi's portfolio of leading hematology medicines through CTI's lead product, VONJO® (pacritinib), which is FDA-approved for the treatment of adult myelofibrosis patients with a platelet count below 50 x109/L.
Lead Product(s): Pacritinib
Therapeutic Area: Oncology Product Name: Vonjo
Highest Development Status: Phase IVProduct Type: Small molecule
Recipient: CTI BioPharma Corp
Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million
Deal Type: Acquisition May 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
